Biohaven Ltd. (BHVN), a global clinical-stage biopharmaceutical company developing therapies for the treatment of a broad range of rare and common diseases, has a couple of clinical and regulatory catalysts worth watching in the coming months.
The most immediate catalyst is the anticipated topline data from one of the two phase III trials of Troriluzole in subjects with obsessive compulsive disorder, expected in the first half of this year.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.